-+ 0.00%
-+ 0.00%
-+ 0.00%
Sanofi's Infilbray Secures US Nod as Treatment for Gaucher Disease Neurological Manifestations
Share
Listen to the news
11:11 PM EST, 11/18/2026 (MT Newswires) -- Sanofi (SAN.PA) received approval from the US Food and Drug Administration for Infilbray, or venglustat, as a treatment for the neurological manifestations of type 3 Gaucher disease in both adults and pediatric patients with a weight of at least 15 kilograms. The French pharmaceutical company said Wednesday that it supported the application for the drug with results from the phase 3 Leap2Mono study, which showed statistically significant superiority for Infilbray in neurological manifestation improvement, compared with enzyme replacement therapy imiglucerase. Infilbray previously received breakthrough therapy designation, rare pediatric disease designation, and fast-track designation in the US, as well as orphan designation for type 3 Gaucher disease in the European Union, US, and Japan. The treatment was accepted for priority review in the US and is under regulatory review in the EU, Japan and other jurisdictions globally. Sanofi will pursue additional global regulatory submissions for Infilbray in 2026 and 2027.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending